️Macro Alpha Analytics
الذهاب إلى القناة على Telegram
欢迎加入 【Macro Alpha Analytics】 ⚖️ 法律声明 : 📌 分享性质: 本群所有观点纯属个人意见分享,不构成买卖建议 (No Buy/Sell Recommendation)。 📌 专业咨询: 在做出任何投资决定前,请务必咨询专业持牌理财顾问或您的股票经纪。 📌 责任豁免: 阁下须对自身的财务决策负全责。本群不对任何投资亏损、交易风险或决策后果承担任何法律责任。 ⚠️ 风险提示: 市场波动无常,投资需根据自身财务承受能力审慎操作。
إظهار المزيد6 444
المشتركون
لا توجد بيانات24 ساعات
-307 أيام
-14730 أيام
أرشيف المشاركات
Azam Jaya Berhad (NR, FV RM1.20) – Affin Hwang IB
Connecting the Land below the Wind
Pure-play Sabahan contractor with an exposure to infrastructure projects – mainly roadworks. Notably, they are involved in both Phase 1A and 1B of the PBH. Outstanding orderbook is at RM1.45bn, with YTD wins of RM1.13bn consisting of 3 packages of the PBH Phase 1B.
We see Azam Jaya as a proxy to elevated infrastructure spending in Sabah. We estimate 3-years EPS CAGR of 22% in 2024-26E, mainly driven by the PBH projects secured this year and assuming RM500m p.a. of orderbook replenishment. FV of RM1.20 derived from pegging our 2025E EPS of 8.6 sen to 14x PER, a c. 30% discount to comparable peers weighted average of 20x. Set to list on 11/11 at IPO price of RM0.78, 15x 2023 PER which is at a discount to comparable peers.
1. Sabah-based infrastructure contractor, principally involved in roads, highways, bridges, tunnels. They built the first flyover, longest bridge and first and only vehicular tunnel in the state. Most notably involved in Phase 1A and 1B of the PBH, with intention to tender for further phases.
2. Well poised to leverage on elevated infrastructure spending. Government allocated 7.8% of DE in Budget 2025 to Sabah – highest in 4 years. RM13bn for 488 infrastructure projects have also been set aside. PBH won this year will sustain revenue for the next 4 years, while smaller packages of roadworks will provide further upside before the lucrative PBH Phase 2 and 3 is called for tender.
3. 6% market share in a fragmented industry commendable. Using the PBH as an illustration, where 13 contractors were appointed for 19 packages implying a fragmented infrastructure construction scene in Sabah. On a relative basis, 6% market share seems to be decent. Azam Jaya won 3/19 of the PBH Phase 1B, worth RM1.13bn or 8% of RM14bn expected construction cost.
4. IPO valuations of 15x CY23 PER at a c. 48% discount to comparable peers weighted average. Very enticing, given their unique position as an infrastructure specialist with a heavy presence in Sabah.
5. FV of RM1.20 – pegged 2025E EPS of 8.6 sens to 14x PE. Implying a 54% upside to IPO price. 3 years earnings CAGR of 22% over 2024E-2026E. 3 packages of the PBH project won this year will be main driver for earnings, while our RM500m contract replenishment assumption per year will provide earnings upside over the previous years. Pegged 2025E EPS to 14x PE, a c. 30% discount to comparable peers weighted average due to the premium on the big caps.
10 نوفمبر 2024, 19:42
🔔Today New Listing - 11/11/2024🔔
Mega Fortris Berhad (5327)
Market: Main
Oversubscription rate: 7.18X
IPO Price : RM 0.67
Fair value given:
1. Mplus RM 0.85
2. TA RM 0.75
10 نوفمبر 2024, 19:20
🔔Today New Listing - 11/11/2024🔔
Azam Jaya Berhad (5329)
Market: Main
Shariah Compliant ✅
Oversubscription rate: 23.0X
IPO Price : RM 0.78
Fair value given:
1. RHB RM 1.04
2. TA RM 1.54
3. Public RM 1.00
4. Rakuten RM 1.56
5. Mplus RM 1.47
10 نوفمبر 2024, 19:20
Mattar Residences achieves new high of $2,400 psf
https://www.edgeprop.sg/property-news/mattar-residences-achieves-new-high-2400-psf
09 نوفمبر 2024, 22:35
- Deglobalisation, accessing into India.
- New biz – seeing a lot of demand for KGD solution and wide band gap power supply final tests + SiC wafer equipment.
- SiC wafer equipment can do 6-8 wafers at one go.
- KGD required final packaged test as well.
- *Automotive market taking a breather* after a high base back then. US, EUR and CN still seeing a lot of onshoring, but not expecting huge growth in short time span.
- Just came back from Taiwan, *seeing uptick in capex spending cycle for advanced packaging*, seeing application for SiC are broadening due to price drop.
- Looking forward to 2025, seeing pick up in activities. Working on advanced packaging of 2.5D equipment.
- Competition in China is very fierce, some are selling at losses to build up market share.
- The group has been awarded, 5th time in Forbes’ Asia’s Best Under A Billion in Aug24.
- Revenue target of RM1b in 2025, pushed back to 2026.
*Q&A*
- Major medical customer in Penang – formed bulk of the orderbook. But other medical customers are gaining traction – eg dental cap.
- No exposure on ozempic medtech as yet.
- Visibility from KGD mostly from Auto, CN and EUR.
- Automotive: 50% from CN’s MNC. Very concentrated in 1=2 players.
- Most recent replenishment, coming from ATE (automotive) and FAS (medical).
- Potential breakthrough in 2025, to be catalyzed by Electro optical (seeing an inflection point), Medical and advanced packaging for FAS and ATE
- Active alignment – on CoWoS, process required TIA and Penta is working on it. Working on vision as well.
- CE – some of the anchor customers are involving in FAS requirement for DC on AI.
- MediQ – aim is to move into Campus 3 by early 2025, the teams have travelled overseas to sign a few MoU with the local governments. Identified certain markets for penetration. To start of with IVC, to expand product portfolio (manufacturing activities and collaborative manners to sell products). Looking to get approved permit to penetrate into Halal market. But expect some gestation period.
- IGBT - seeing some activities from Taiwan / Japan but does not foresee any significant contribution like prior years given the SiC current prices.
- Major medical customer from Penang to lead revenue through 1Q/2025. New medical customers (hearing aid) - revenue contribution is not as meaningful as this major medical customer as yet.
- 2025: Revenue exposure from medical to be 40-45%. Seeing momentum from new customers, there could be more traction in 2025.
- ATE contribution mostly by BE in 3Q24.
09 نوفمبر 2024, 18:47
From UOBKH : ♨️ Fresh From Oven ♨️
Pentamaster meeting keytakes (Zoom)
Date: 8 Nov 2024
Management: Julia Gan (CFO), Kean Yong (Director)
Key takeaways:
- 3Q revenue came in lower at RM150.1m, -12% qoq and -17% yoy
- FAS>ATE, 62:38, +85%/-48%, well guided with the orderbook visibility
- Mix: 26% automotive, 47% medical, 14% CE/Industrial, 8% Semicon, 5% CE/Industrial
- *Medical* +140%, leading within the FAS segment, driven by the prevalence of medical automation - i-ARMS. Delivered first prototype lines in 1H to new medical customers and seeing repeat orders on i-ARMS. Expect revenue contribution of 45-48%.
- *Automotive* contributed 26%, -53% yoy hence ATE -48%. Revenue mainly derived from PO of China 50% (slow), MY 18%, US, VN, EUR and JPN. Still have a good spread of exposure. Experienced slower than expected orders. Still seeing softness though there are still orders inflow. US and EUR markets are still uncertain. CN market is highly competitive. Still pursuing with China market. Seeing demand inflow of KGD handler in 3Q24. Seeing qoq improvement but no big booking. Revenue contri to be 25-28%.
- *Electro-Optical* contributed 14%, mainly on smart sensor + ambient light sensor related test equipment. Still seeing steady demand, revenue contri to be 10-12%. Expect more robust outlook in 2025 underpinned by ambient + flagship solution for proximity sensors.
- *Semicon* contributed 8% (-48% due to industry softness early 24), relatively stable. Some growth in 3Q24. Revenue contri to be 10%. Hopeful to see growth in 2025 by advanced packaging solutions
- *CE/Industrial*, 3Q +18% qoq, contribution at 5%. Expect revenue contri of 5%. Outlook: Contributing to FAS segment, group to have each BU to have its own anchor customers. Hopeful of new customers coming on board.
- Top 5 customers: Medical, Automotive and Electro-Optical, from diff geographical areas.
*Financials*
- *3Q24 GPM 28.8%* vs vs 30.5% in 3Q24 and 28.1% in 2Q24. Improvement in QoQ margins on better product mix. 3Q24 seeing impressive GPM due to FAS gpm’s of 36%.
- 9M24 GP dropped yoy, owing to softness from ATE’s Automotive + additional bonus in 1Q24 + R&D dev costs affected.
- Key items under SG&A: Staff costs in Admin, R&D for single used medical, have to be charged it out. If the group were to strip out forex elements in SG&A, expenses would have been decent.
- Forex + derivative movement – on USD volatility (depreciation).
- *Bulk of forex losses remain unrealized,* yet to be converted back.
- PIL net profit and PCB net profit – a gap of RM5m (unrealized).
- Operation wise, net loss was at RM4.8m at PIL, but PCB at RM9m due to HKD exposure (dividend).
- NP and taxation – dropped in ETR (1ppts) due to FAS contribution with unabsorbed tax losses.
- Applying pioneer status for FAS and ATE, as some are expiring in 2026.
- Sitting on RM367m in PIL.
- +ve OCF were used to finance expansion in campus 3
- *Orderbook at RM420m* – mainly from Medical + Auto at >60%. ATE 40%, FAS 60%.
- MediQ, to move in early 2025.
- Capex: budgeted RM300m earlier, spent RM250m. Moving forward, there will be some additional capex for Campus 3’s warehouse of RM30m. RM1m for IT infra. Plant 2: close to finalizing on leasing agreement.
- Headcount at 952, careful in expending.
- HQ BU 140k sqft, Campus 2 BU at 100k sqft, Campus 3: 720k sqft in BK.
- *Expect flat revenue momentum in 2024, best case scenario*, or slight drop of 5%.
*Corporate development*
09 نوفمبر 2024, 18:47
PENTA (BUY ↔️; TP: RM4.40 🔽)
❗️*Analyst report update*: Cut EPS by 11–19% to account for lower ATE vol amid sluggish auto sector recovery and updated our fx assumptions. Revised down TP on lower 31x PE (-1SD 5-year mean), from 35x (mean) to reflect the patchy auto recovery
📰 Briefing takeaways (8 Nov, 11AM)
* 62% FAS contribution in 9M24 (35% in 2023)
* *Medical* revenue (+135% yoy) > auto (-53% yoy) in 9M24. Driven by increasing automation adoption especially from MedTech sector. *Seeing repeat orders from new customers.* Key client, stronger contribution in 4Q24 and maybe spilling over to 2025. Combined new customers 10-15% & key customer 85%)
* % medical revenue for FY24 will be c.48-49% (similar to 9M24). 40-45% for 2025
* *Auto* revenue (26% 9M24). *Outlook still slow*. Recovery taking longer than mgmt expected. US and EU still uncertain. China intense competition. Still actively engage customers
* % auto revenue for FY24 will be c.25% (similar to 9M24)
* KGD testers demand stable qoq in 4Q24 and 2025. But not in a big way. Small stable vol for now
* *Expect better electro-optical outlook* in 2025. Will see revenue growth from sensor and proximity sensor. Already received PO, but delivery next year
* *Consumer/industrial* rev rose 18% qoq in 3Q. ea biz unit 1 anchor customer (set KPI). Expect to onboard some new customers and more repeat customers. Contribution still small 5%. Expect growth in 2025
* *RE:* Seeing some repeat orders. More recognition in 2025
* *ATE outlook*: Rising demand from new sensor technology. Upgrading capability to expand from consumer to auto
* See stronger demand for new KGD equipment
* Top-5 customers: Med, auto & electro-optical
* *Headline margin fall* on lower revenue (9M24: -6%), higher R&D and bonus, but mitigated higher margin FAS contribution. Core margin higher
* 9M24 *eff. tax rate -1ppts*: FAS subsi have some unabsorbed tax loss. Pioneer status expiring 2026
* Moving FAS to new Campus3 (by y/e). Start production by 1Q25
* MediQ to move beg. 2025 (signed few MoU with local GLC, Identified few markets). Expand product portfolio. Will focus manufacturing
* *Capex 2025*: Campus3: warehouse (RM30m), furniture and fitting (RM5m), IT infra (RM1m). Campus2: finalizing leasing agreement (earning rental income)
* 950 employees
* TW capex feedback. Broadening SiC usage for lower powered app. Power rack for servers (increasing %). TSMC/Nvidia AI adv packaging spilling to BE. Opp: TIA/CoWos 2.5/3D packaging
* Still seeing fierce China competition
* Latest *O/B*: RM420m FAS:ATE 60:40. FAS mostly medical/its key customer. But application include hearing aid, dental care
* Auto O/B (50% from China) -> mostly MNC; 1-2 customer. Mainly SiC, X IGBT
* 3Q24 O/B replenishment RM170m from FAS (med) & ATE (auto)
2024 rev guidance: flat (best case). Worst case: -X% decline.
2025: seeing activity pick up (little visibility) & focus on improve margin, but internal target grow XX%. Push RM1bn rev target to FY26 (Phillip E: RM830m)
09 نوفمبر 2024, 18:45
近期的 IPOs 比较厉害,都是 100X 倍起跳的 ‼️😆 其中最厉害的还是这家 #SCB ▶️ 213.53X 。
09 نوفمبر 2024, 00:20
以往 IPO 的超额认购 ▶️
1⃣ NationGate: 16.49X
2⃣ MasterTec : 7.11X
3⃣ Synergy House : 14.02X
4⃣ Infomina : 21.39X
5⃣ Papajack : 21.73X
6⃣ Wellspire : 11.00X
7⃣ LGMS : 24.00X
8⃣ SFPTECH : 41.61X
09 نوفمبر 2024, 00:16
